110 related articles for article (PubMed ID: 19294626)
1. Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial.
Olioso P; Giancola R; Di Riti M; Contento A; Accorsi P; Iacone A
Hematol Oncol; 2009 Sep; 27(3):130-9. PubMed ID: 19294626
[TBL] [Abstract][Full Text] [Related]
2. CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma.
Pan QZ; Liu Q; Zhou YQ; Zhao JJ; Wang QJ; Li YQ; Tang Y; Gu JM; He J; Chen SP; Weng DS; Xia JC
Cancer Immunol Immunother; 2020 May; 69(5):825-834. PubMed ID: 32060687
[TBL] [Abstract][Full Text] [Related]
3. Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up.
Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
Cancer Immunol Immunother; 2019 Jan; 68(1):23-32. PubMed ID: 30232520
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma.
Su X; Zhang L; Jin L; Ye J; Guan Z; Chen R; Guo T
Cancer Biother Radiopharm; 2010 Aug; 25(4):465-70. PubMed ID: 20701541
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.
Schmidt-Wolf IG; Lefterova P; Mehta BA; Fernandez LP; Huhn D; Blume KG; Weissman IL; Negrin RS
Exp Hematol; 1993 Dec; 21(13):1673-9. PubMed ID: 7694868
[TBL] [Abstract][Full Text] [Related]
6. Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells.
Gammaitoni L; Giraudo L; Macagno M; Leuci V; Mesiano G; Rotolo R; Sassi F; Sanlorenzo M; Zaccagna A; Pisacane A; Senetta R; Cangemi M; Cattaneo G; Martin V; Coha V; Gallo S; Pignochino Y; Sapino A; Grignani G; Carnevale-Schianca F; Aglietta M; Sangiolo D
Clin Cancer Res; 2017 May; 23(9):2277-2288. PubMed ID: 27815354
[No Abstract] [Full Text] [Related]
7. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
Lee JH; Lee JH; Lim YS; Yeon JE; Song TJ; Yu SJ; Gwak GY; Kim KM; Kim YJ; Lee JW; Yoon JH
Gastroenterology; 2015 Jun; 148(7):1383-91.e6. PubMed ID: 25747273
[TBL] [Abstract][Full Text] [Related]
8. Autologous Cytokine-Induced Killer Cells Improves Overall Survival of Metastatic Colorectal Cancer Patients: Results From a Phase II Clinical Trial.
Zhao H; Wang Y; Yu J; Wei F; Cao S; Zhang X; Dong N; Li H; Ren X
Clin Colorectal Cancer; 2016 Sep; 15(3):228-35. PubMed ID: 27052743
[TBL] [Abstract][Full Text] [Related]
9. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer.
Pan K; Guan XX; Li YQ; Zhao JJ; Li JJ; Qiu HJ; Weng DS; Wang QJ; Liu Q; Huang LX; He J; Chen SP; Ke ML; Zeng YX; Xia JC
Clin Cancer Res; 2014 Jun; 20(11):3003-11. PubMed ID: 24668644
[TBL] [Abstract][Full Text] [Related]
10. Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy.
Zhang Y; Wang J; Wang Y; Lu XC; Fan H; Liu Y; Zhang Y; Feng KC; Zhang WY; Chen MX; Fu X; Han WD
Clin Dev Immunol; 2013; 2013():195691. PubMed ID: 24382970
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer.
Shi L; Zhou Q; Wu J; Ji M; Li G; Jiang J; Wu C
Cancer Immunol Immunother; 2012 Dec; 61(12):2251-9. PubMed ID: 22674056
[TBL] [Abstract][Full Text] [Related]
12. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study.
Li R; Wang C; Liu L; Du C; Cao S; Yu J; Wang SE; Hao X; Ren X; Li H
Cancer Immunol Immunother; 2012 Nov; 61(11):2125-33. PubMed ID: 22581306
[TBL] [Abstract][Full Text] [Related]
13. DC-CIK as a widely applicable cancer immunotherapy.
Wang S; Wang X; Zhou X; Lyerly HK; Morse MA; Ren J
Expert Opin Biol Ther; 2020 Jun; 20(6):601-607. PubMed ID: 32033522
[No Abstract] [Full Text] [Related]
14. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.
Mesiano G; Todorovic M; Gammaitoni L; Leuci V; Giraudo Diego L; Carnevale-Schianca F; Fagioli F; Piacibello W; Aglietta M; Sangiolo D
Expert Opin Biol Ther; 2012 Jun; 12(6):673-84. PubMed ID: 22500889
[TBL] [Abstract][Full Text] [Related]
15. Treatment Options for Hepatocellular Carcinoma Using Immunotherapy: Present and Future.
Wei H; Dong C; Li X
J Clin Transl Hepatol; 2024 Apr; 12(4):389-405. PubMed ID: 38638377
[TBL] [Abstract][Full Text] [Related]
16. Optimizing tumor-associated antigen-stimulated autologous dendritic cell and cytokine-induced killer cell coculture to enhance cytotoxicity for cancer immunotherapy in manufacturing.
Lee YY; Luo SC; Lee CH; Tang CL; Shen CC; Cheng WY; Yang YC; Yang MY; Yen CM
BMC Immunol; 2023 Jun; 24(1):14. PubMed ID: 37386444
[TBL] [Abstract][Full Text] [Related]
17. Immunophenotype and antitumor activity of cytokine-induced killer cells from patients with hepatocellular carcinoma.
Yang CK; Huang CH; Hu CH; Fang JH; Chen TC; Lin YC; Lin CY
PLoS One; 2023; 18(1):e0280023. PubMed ID: 36598909
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy and Hepatocellular Cancer: Where Are We Now?
Valery M; Cervantes B; Samaha R; Gelli M; Smolenschi C; Fuerea A; Tselikas L; Klotz-Prieux C; Hollebecque A; Boige V; Ducreux M
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139683
[TBL] [Abstract][Full Text] [Related]
19. NK and cells with NK-like activities in cancer immunotherapy-clinical perspectives.
Mortezaee K; Majidpoor J
Med Oncol; 2022 Jun; 39(9):131. PubMed ID: 35716327
[TBL] [Abstract][Full Text] [Related]
20. Comparison of international guidelines for early-phase clinical trials of cellular and gene therapy products.
Shin W; Kim MG; Kim A
Transl Clin Pharmacol; 2022 Mar; 30(1):13-23. PubMed ID: 35419313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
